Literature DB >> 24057288

Long-term cardio- and cerebrovascular events in patients with primary aldosteronism.

Paolo Mulatero1, Silvia Monticone, Chiara Bertello, Andrea Viola, Davide Tizzani, Andrea Iannaccone, Valentina Crudo, Jacopo Burrello, Alberto Milan, Franco Rabbia, Franco Veglio.   

Abstract

BACKGROUND: Aldosterone plays a detrimental role on the cardiovascular system and PA patients display a higher risk of events compared with EH.
OBJECTIVES: The objectives of the study were to compare cardio- and cerebrovascular events in patients with primary aldosteronism (PA) and matched essential hypertension (EH).
METHODS: We retrospectively compared the percentage of patients experiencing events at baseline and during a median follow-up of 12 years in 270 PA patients case-control matched 1:3 with EH patients and in PA subtypes [aldosterone-producing adenoma (n = 57); bilateral adrenal hyperplasia (n = 213)] vs matched EH.
RESULTS: A significantly higher number of PA patients experienced cardiovascular events over the entire period of the study (22.6% vs 12.7%, P < .001). At the diagnosis of PA, a higher number of patients had experienced total events (14.1% vs 8.4% EH, P = .007); furthermore, during the follow-up period, PA patients had a higher rate of events (8.5% vs 4.3% EH, P = .008). In particular, stroke and arrhythmias were more frequent in PA patients. During the follow-up, a higher percentage of PA patients developed type 2 diabetes. Parameters that were independently associated with the occurrence of all events were age, duration of hypertension, systolic blood pressure, presence of diabetes mellitus, and PA diagnosis. After division into PA subtypes, patients with either aldosterone-producing adenoma or bilateral adrenal hyperplasia displayed a higher rate of events compared with the matched EH patients.
CONCLUSIONS: This study demonstrates in a large population of patients the pathogenetic role of aldosterone excess in the cardiovascular system and thus the importance of early diagnosis and targeted PA treatment.

Entities:  

Mesh:

Year:  2013        PMID: 24057288     DOI: 10.1210/jc.2013-2805

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  119 in total

1.  Evolution of computed tomography-detectable adrenal nodules in patients with bilateral primary aldosteronism.

Authors:  Paolo Mulatero; Jacopo Burrello; Barbara Lucatello; Gilberta Giacchetti; Marialberta Battocchio; Francesco Fallo
Journal:  Endocrine       Date:  2015-12-08       Impact factor: 3.633

2.  Different Somatic Mutations in Multinodular Adrenals With Aldosterone-Producing Adenoma.

Authors:  Fabio Luiz Fernandes-Rosa; Isabelle Giscos-Douriez; Laurence Amar; Celso E Gomez-Sanchez; Tchao Meatchi; Sheerazed Boulkroun; Maria-Christina Zennaro
Journal:  Hypertension       Date:  2015-09-08       Impact factor: 10.190

Review 3.  Endocrine Tumors Causing Arterial Hypertension: Pathophysiological Mechanisms and Clinical Implications.

Authors:  Agata Buonacera; Benedetta Stancanelli; Lorenzo Malatino
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-04-12

Review 4.  Issues in the Diagnosis and Treatment of Primary Aldosteronism.

Authors:  Jacopo Burrello; Silvia Monticone; Fabrizio Buffolo; Martina Tetti; Giuseppe Giraudo; Domenica Schiavone; Franco Veglio; Paolo Mulatero
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-04-09

5.  Lateralization index but not contralateral suppression at adrenal vein sampling predicts improvement in blood pressure after adrenalectomy for primary aldosteronism.

Authors:  M Tagawa; M Ghosn; H Wachtel; D Fraker; R R Townsend; S Trerotola; D L Cohen
Journal:  J Hum Hypertens       Date:  2017-01-12       Impact factor: 3.012

Review 6.  Primary aldosteronism: a common cause of resistant hypertension.

Authors:  Gregory A Kline; Ally P H Prebtani; Alexander A Leung; Ernesto L Schiffrin
Journal:  CMAJ       Date:  2017-06-05       Impact factor: 8.262

Review 7.  The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment.

Authors:  Anand Vaidya; Paolo Mulatero; Rene Baudrand; Gail K Adler
Journal:  Endocr Rev       Date:  2018-12-01       Impact factor: 19.871

Review 8.  Familial hyperaldosteronism type III.

Authors:  S Monticone; M Tetti; J Burrello; F Buffolo; R De Giovanni; F Veglio; T A Williams; P Mulatero
Journal:  J Hum Hypertens       Date:  2017-04-27       Impact factor: 3.012

Review 9.  Aldosterone excess and resistant hypertension: investigation and treatment.

Authors:  Michael Stowasser
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

Review 10.  Hyperaldosteronism: Screening and Diagnostic Tests.

Authors:  Chiara Sabbadin; Francesco Fallo
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.